Clovis Oncology, Inc. (CLVS)
| Market Cap | 625.09M |
| Revenue (ttm) | 164.52M |
| Net Income (ttm) | -369.21M |
| Shares Out | 84.31M |
| EPS (ttm) | -4.38 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 19 |
| Last Price | $5.83 |
| Previous Close | $5.98 |
| Change ($) | -0.16 |
| Change (%) | -2.59% |
| Day's Open | 5.89 |
| Day's Range | 5.79 - 6.14 |
| Day's Volume | 2,799,044 |
| 52-Week Range | 4.08 - 11.10 |
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Highlights Rubraca® (rucaparib) Clinical Data at AACR Virtual Annual Meeting 2021
Immutep Limited (IMMP) stock is soaring higher on Thursday despite a lack of recent news coming from the company but there is a reason why. The post IMMP Stock: Why Is Biotech Company Immutep Rocketing ...
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock?
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
Clovis (CLVS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the n...
The biotech's experimental cancer treatment demonstrated promising results in a clinical trial.
Clovis Oncology Inc. (NASDAQ:CLVS) shares are gaining ground in Friday's session. The jump in the shares comes after a company announcement stating that Rubraca significantly improves progression-free s...
Clovis Oncology, Inc. (NASDAQ: CLVS), Marker Therapeutics, Inc. (NASDAQ: MRKR) and Alector, Inc. (NASDAQ: ALEC) are among the biggest biotech gainers Friday. Clovis Jumps On Ovarian Cancer Data: Clovis ...
Biotech company Clovis Oncology has shown promising info regarding the treatment of ovarian cancer. CLVS stock has benefitted from the data.
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS) announced that the first presentation of data from the randomized, Phase 3 ARIEL4 study of Rubraca® (rucaparib) will take place toda...
CLVS stock should attract buyers because declining coronavirus cases offer more opportunities to serve cancer patients. But the economic narrative confirms that the bears may have a point in their pessi...
Clovis (CLVS) reports wider-than-expected loss for fourth-quarter 2020. Sales of the company's sole marketed drug, Rubraca, increase year over year.
Shares of Clovis Oncology (NASDAQ:CLVS) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share rose 59.12% year over year to ($0.74), which beat the estimate of ...
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter and year ended December 31, 2020, and provided an update on the Company's clinic...
The next GME will be hard to find, but these three stocks could be solid candidates for a potential short squeeze. The post 3 Troll-able Stocks That Could Be the Next GME appeared first on InvestorPlace.
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter and year-end 2020 financial results on Tuesday, February 23, 2021, before the open of the...
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Presents Data in Advanced Prostate Cancer at ASCO GU 2021 Virtual Meeting
Hasbro, Nautilus, Clovis Oncology and XPeng were our top stock trades Tuesday. Let's have a look at the charts to see how they're setting up.
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that two abstracts featuring data from clinical studies evaluating Rubraca® (rucaparib) in metastatic cast...
Unless they were on another planet last week, everybody saw the gigantic moves in companies with huge short interest.
Clovis Oncology: Recent Rally Already Has Me Changing My Game Plan
The movement of retail traders against hedge funds has caused several stocks to spike. Many of the top movers have been stocks that have a high percentage of their floated shares short, causing what's k...
Despite COVID-19, sales will hit a record for the fourth quarter. Company expecting plenty of milestones concerning its ongoing trials in 2021.
Morgan Stanley, Halliburton, Procter & Gamble and Clovis Oncology were our top stock trades for Wednesday. Now, let's look at the charts.
Penny stocks are cheap for a reason, as there are obvious flaws. However, with those flows comes opportunity.
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended December 31, ...
Clovis (CLVS) submits regulatory application to the FDA for initiating clinical study on its peptide-targeted radionuclide therapy, FAP-2286.
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the company has completed submission of two Investigational New Drug (IND) applications to the U.S. F...
Clovis' (CLVS) Rubraca achieves significant improvement in progression free survival compared to chemotherapy in late-stage confirmatory study for BRCA-mutated ovarian cancer indication.
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS), today announced topline data from the randomized Phase 3 ARIEL4 study of Rubraca, which met its primary endpoint of impro...
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock?
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology Announces Exercise by Existing Holder of Option to Purchase an Additional $7.5 Million Aggregate Principal Amount of the Company's 4.5
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology to Present at the Piper Sandler 32nd Annual Healthcare Conference
Clovis (CLVS) reports mixed third-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially.
Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q3 2020 Results - Earnings Call Transcript
Clovis (CLVS) delivered earnings and revenue surprises of 11.88% and -8.42%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2020, and provided an update on the Company's clinical devel...
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Announces Debt Exchange Transaction and Offering of Convertible Senior Notes
Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2020 financial results on Thursday, November 5, 2020, before the open of the U.S. financia...
Despite an almost 60% rise since the March 23 lows of this year, at the current price of around $6 per share, we believe Clovis Oncology stock has more room for growth. CLVS stock has rallied from under...
BOULDER, Colo.--(BUSINESS WIRE)--New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology Announces Oral Plenary Session Presentation at International Gynecologic Cancer Society (IGCS) Digital Annual Global Meeting
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology to Highlight Data for its Three Portfolio Compounds at the ESMO Virtual Congress 2020
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology to Present at the H.C.
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock?
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--FDA Approves FoundationOne® Liquid CDx to Serve as Rubraca® (rucaparib) Companion Diagnostic to Identify Eligible Patients with BRCA1/2-Mutant, mCRPC
BOULDER, Colo.--(BUSINESS WIRE)--JCO Publishes Additional Data from CLVS TRITON2 Clinical Trial Evaluating Rubraca® for the Treatment of mCRPC in Patients with BRCA1/2 Gene Mutations
About CLVS
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. It also provides lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth f... [Read more...]
| Industry Biotechnology | IPO Date Nov 16, 2011 |
| CEO Patrick Mahaffy | Employees 429 |
| Stock Exchange NASDAQ | Ticker Symbol CLVS |
Financial Performance
In 2020, CLVS's revenue was $164.52 million, an increase of 15.05% compared to the previous year's $143.01 million. Losses were -$369.21 million, -7.79% less than in 2019.
Analyst Forecasts
According to 7 analysts, the average rating for CLVS stock is "Hold." The 12-month stock price forecast is 7.13, which is an increase of 22.40% from the latest price.